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Original Article of Interventional Pulmonology Corner

Airway stent complications: the role of follow-up bronchoscopy as
a surveillance method
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Background: Airway stenting has become an integral part of the therapeutic endoscopic management
of obstructive benign and malignant central airway diseases. Despite increased use of airway stents and
frequent stent-associated complications, no clear guidelines for surveillance and maintenance exist. This
study aim is to elucidate predictive factors associated with development of stent complications, as well as an
optimal surveillance period for follow-up bronchoscopy for early detection and possible prevention of stentassociated complications.
Methods: Retrospective cohort study of all patients who underwent airway stent placements at our
institution from April 2010 to December 2013 for benign and malignant airway diseases. Metallic, silicone
(straight, Y stent, T-tube) and hybrid stents were included in the study. Stent complications were analyzed
at the time of follow-up bronchoscopy performed four to six weeks after initial stent placement or earlier if
patients became symptomatic.
Results: The study included 134 patients of which 147 stents were placed. Follow-up bronchoscopy was
performed in 94 patients. Symptomatic status at the time of follow-up bronchoscopy was not associated
with stent complications [odds ratio (OR) =1.88; 95% CI: 0.79–4.45; P=0.15]. Patient age, sex, indication
for stent placement, and stent location, were not associated with development of complications (all P>0.05).
Compared to all other stents, hybrid stents were more likely to migrate (OR =6.60; 95% CI: 2.16–20.2;
P=0.001) or obstruct by secretions (OR =2.53; 95% CI: 1.10–5.84; P=0.03). There were no complications
associated with surveillance bronchoscopy.
Conclusions: Surveillance bronchoscopy within 4 to 6 weeks of stent placement may be useful for
early detection of complications and their subsequent management, regardless of symptomatic status and
indication for stent placement. Prospective multicenter studies are needed to compare optimal surveillance
methods and the impact on patient mortality, morbidity and healthcare costs.
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Introduction
Over the past two decades, airway stenting has become an
integral part of the therapeutic endoscopic management of
obstructive benign and malignant central airway diseases.
Airway stent insertions often achieve immediate relief of
dyspnea (1-6). Moreover, airway stenting has consistently
improved airflow obstruction parameters on pulmonary
function testing (3,7-10). Significant improvement in
the Eastern Cooperative Oncology Group (ECOG)
performance score has also been reported in patients with
malignant disease after stent placement (2,11).
Along with well-established palliative and therapeutic
benefits, stent-related complications have also been
reported with use of metallic and silicone stents
(2,5,12-17). These include stent migrations, stent fractures,
stent-associated infections, and stent obstructions by tumor,
granulation tissue and secretions. Follow-up endoscopic
interventions are often needed to maintain airway patency
and prevent further complications (6,12,17). Despite
increased use of airway stents and frequent stent-associated
complications, most interventional pulmonologists do not
have defined follow-up or maintenance protocols to adhere
to (18).
This study represents our institutional experience
of various airway stent placements and follow-up
bronchoscopies for management of obstructive benign and
malignant central airway diseases. The study hypothesis
is that follow-up bronchoscopy 4-6 weeks after stent
placement allows for early detection of stent-related
complications regardless of symptomatic status, which may
serve as an optimal surveillance point to prevent further
respiratory complications.
Methods
Study design
We performed a retrospective cohort study of all patients
who underwent placement of at least one airway stent at
the Johns Hopkins Hospital from April 2010 to December
2013. Patients were identified using the following
current procedural terminology (CPT) codes: 31631
[bronchoscopy, rigid or flexible, including fluoroscopic
guidance, when performed; with placement of tracheal
stent(s)], 31636 [bronchoscopy, rigid or flexible, including
fluoroscopic guidance, when performed; with placement
of bronchial stent(s), initial bronchus], and 31637
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[bronchoscopy, rigid or flexible, including fluoroscopic
guidance, when performed; each additional major
bronchus stented].
The study was approved by the Johns Hopkins
institutional review board (00028714) with waiver to
informed consent provided. Patient data was retrieved
from electronic medical records using a standardized form.
All definitions were developed prior to chart abstraction
to ensure consistency. Demographic (age, gender), stent
data (stent type, location, and indication) and surveillance
bronchoscopy findings were collected.
Follow-up bronchoscopy was performed according to
the clinical protocol of our department for airway stenting,
between 4–6 weeks following stent insertion or if patients
became symptomatic, whichever occurred earlier. For
patients who underwent a follow-up bronchoscopy any
time after the initial stent insertion, we abstracted data on
the type of bronchoscope used, symptomatic status prior
to the bronchoscopy, stent-related complications, and
therapeutic interventions performed during bronchoscopy.
The primary outcome was development of stent-related
complications, defined as stent migrations/fractures or
obstruction by tumor, granulation tissue or secretions
detected on follow-up bronchoscopy.
Statistical analysis
Patient and stent characteristics are presented overall,
and by follow-up bronchoscopy status as means (standard
deviations) for continuous variables and as percentages
for categorical variables. Characteristics by follow-up
bronchoscopy status were compared using Student’s
t-tests and chi square tests. Clustering of stents within
patients who had more than one stent placed during initial
bronchoscopy was accounted for using the generalized
estimating equations (GEE) model with independent
correlation structure. Odds ratios (ORs) (with 95% CIs)
for the presence of complications among those who
underwent follow-up bronchoscopy were obtained from
the GEE models. Univariate and multivariate analyses
were performed. Variables included in the models were:
age, sex, indication for stent placement, stent location,
stent type and symptoms at the time of follow-up
bronchoscopy. All reported P values are two-sided and
P<0.05 was considered statistically significant. All analyses
were performed using Stata Version 13 (StataCorp,
College Station, Texas, USA).
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Results
Patient characteristics
There were 134 patients with central airway obstruction
with a total of 147 airway stents placed. Ten patients had
more than one stent placed during the initial bronchoscopy.
Seventy seven patients (58%) were women (Table 1). Mean
patient age was 55.9±15.5 years. Eighty six patients (64%)
underwent stent placement for malignant airway disease,
half of whom had non-small cell lung cancer, while other
malignant indications included small cell lung cancer,
esophageal cancer, lymphoma, and lung metastases from
variety of primary malignancies (6 sarcoma, 3 breast,
2 renal, 2 thyroid, 1 head and neck, 1 hepatoblastoma and
1 unknown primary).
Leading benign indications for airway stenting (48
patients) were idiopathic or post-intubation tracheal stenosis
(23 patients), as well as post lung transplantation bronchial
stenosis, tracheobronchomalacia, pulmonary aspergillosis,
papillomatosis and tracheoesophageal fistula.
Among the 134 patients, who had an airway stent placed
during the initial bronchoscopy, 94 (70%) had followup bronchoscopy of which 61% were women, 54% had a
malignant indication for stent placement, and 63% were
symptomatic at the time of the bronchoscopy (Table 1).
These 94 patients had a total of 100 stents (5 patients had
more than one stent). The mean time from stent placement
to follow-up bronchoscopy was 41.2 days. There were no
complications associated with follow-up bronchoscopy.
Stent characteristics
The types and locations of the stents inserted during the
initial bronchoscopy are outlined in Table 2. The most
common stent was the hybrid stent (42.9%), followed
by the straight silicone stent (22.4%), and the Y-stent
(20.4%). The metallic stent accounted for only 7.5%
of the stents, as it was taken off the market in 2011. All
metallic stent placements were performed for malignant
airway obstruction only. Of note, all patients with a T-tube
had a follow-up bronchoscopy. Tracheal stents placed for
indications of tracheal stenosis and tracheomalacia were
well represented in the group of patients who underwent
follow-up bronchoscopy.
More than two thirds of all stents placed were associated
with at least one complication at the time of the follow-up
bronchoscopy, such as migration, fracture, and obstruction
by tumor, granulation tissue and secretions (Table 2).
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Nineteen stents were found to have complications within
5 days of placement, requiring therapeutic intervention
during the follow-up bronchoscopy.
Analysis of stent complications
In univariate analysis of patients, who underwent follow-up
bronchoscopy, the presence of dyspnea and having hybrid
stents were independent predictive factors of stent-related
complications (Table 3). Stent-related complications did not
necessarily correlate with respiratory symptoms [odds ratio
(OR) 1.88, 95% CI: 0.79–4.45], as 60% of asymptomatic
patients were found to have at least one stent-related
complication on follow-up bronchoscopy. Moreover, patient
age, sex, and stent indication/location, were not predictive
of development of stent-related complications.
In multivariate analysis, the presence of dyspnea was
no longer an independent predictive factor of stentrelated complications discovered during the follow-up
bronchoscopy (OR 2.36, 95% CI: 0.72–7.70). The hybrid
stents continued to have increased risk of stent-related
complications compared to the metallic, Y, and T-tube
stents (metallic: OR 0.02, 95% CI: 0.002–0.29; Y-stent: OR
0.10, 95% CI: 0.01–0.78; T-tube: OR 0.06, 95% CI: 0.01–
0.60). Of note, the straight silicone stent was associated
with lower odds of complications compared to the hybrid
stent, although this association did not reach statistical
significance (OR 0.17, 95% CI: 0.03–1.00).
Given the higher incidence of stent-related complications
with hybrid stents, we performed further analysis to
determine the likelihood of individual stent-related
complications associated with hybrid stents, compared to all
other stents used in our study. Stent migration (OR =6.60,
95% CI: 2.16–20.2) and stent obstruction by secretions (OR
=2.53, 95% CI: 1.10–5.84) were significantly more likely to
occur with hybrid stents (Table 4).
Discussion
Approximately 30% of patients with lung cancer develop
central airway obstruction and may require airway stents as
part of their management (19). Though surgical resection
remains the gold standard for management of benign
airway stenosis, airway stents can serve as a trial to assess for
symptomatic improvement prior to surgery and also can be
therapeutically utilized in patients with inoperable strictures
or deemed poor surgical candidates due to underlying
comorbidities (20).
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Table 1 Patient characteristics overall and stratified by follow-up bronchoscopy status
All patients (N=134)

Patients with follow-up
bronchoscopy (n=94)

Patients without follow-up
bronchoscopy (n=40)

P value*

55.9 (15.5)

56.1 (13.8)

55.4 (19.1)

0.812

77 (57.5)

57 (60.6)

20 (50.0)

0.254

86 (64.2)

51 (54.3)

35 (87.5)

<0.001

Non-small cell lung cancer

43

20

23

Small cell lung cancer

11

8

3

Esophageal cancer

9

7

2

Lymphoma

5

3

2

Metastases to lung

18

13

5

Tracheal stenosis

23

21

2

Tracheal/bronchial malacia

10

10

0

Airway stenosis after lung transplant

10

10

0

Pulmonary aspergillosis

3

1

2

Other

2

1

1

Flexible

–

47 (50.0)

–

Rigid

–

6 (6.4)

–

Both flexible and rigid

–

41 (43.6)

–

Asymptomatic, n (%)

–

35 (37.2)

–

Symptomatic, n (%)**

–

59 (62.8)

–

Dyspnea, n

–

37

–

Cough, n

–

14

–

Respiratory failure, n

–

10

–

Excess secretions, n

–

4

–

Dysphagia, n

–

3

–

Characteristic
Age (years), mean (SD)
Female, n (%)
Type of airway obstruction, n (%)
Malignant
Malignant airway obstruction causes, n

Benign airway obstruction causes, n

Type of f/u bronchoscopy, n (%)

Symptoms at time of f/u bronchoscopy

*, P value comparing characteristics of patients with and without follow-up bronchoscopy; **, some patients had more than one symptom
at the time of bronchoscopy.
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Table 2 Stent characteristics overall and stratified by follow-up bronchoscopy status
Characteristic

All stents (N=147)

Stents in patients with follow- Stents in patients without follow-up
up bronchoscopy (n=100)
bronchoscopy (n=47)

P value*

Stent type, n (%)
Hybrid (Merit Endotek)

63 (42.9)

40 (40.0)

23 (48.9)

0.31

Metallic (Boston Scientific)

11 (7.5)

6 (6.0)

5 (10.6)

0.32

Straight silicone stent (Novatech)

33 (22.4)

23 (23.0)

10 (21.3)

0.82

Y stent (Novatech)

30 (20.4)

21 (21.0)

9 (19.2)

0.80

T-tube (Boston Medical Products)

10 (6.8)

10 (10.0)

0 (0.0)

0.025

Trachea

44 (29.9)

37 (37.0)

7 (14.9)

0.006

Carina (Y stent)

30 (20.4)

21 (21.0)

9 (19.1)

0.80

Left mainstem bronchus

20 (13.6)

11 (11.0)

9 (19.1)

0.18

Right mainstem bronchus

10 (6.8)

7 (7.0)

3 (6.4)

0.89

Bronchus intermedius

39 (26.5)

24 (24.0)

15 (31.9)

0.31

4 (2.7)

0 (0.0)

4 (8.5)

0.003

No complications, n (%)

–

31 (31.0)

–

Complication found, n (%)***

–

69 (69.0)

–

Obstruction by secretions, n

–

37

–

Obstruction by tumor/granulation
tissue, n

–

27

–

Migration, n

–

20

–

Fracture, n

–

1

–

Distortion, n

–

1

–

No intervention, n (%)

–

26 (26.0)

–

Intervention performed, n (%)****

–

74 (74.0)

–

Aspiration of secretions, n

–

36

–

Stent removal, n

–

27

–

Stent replacement, n

–

13

–

Tumor/GT resection, n

–

12

–

Balloon dilation, n

–

12

–

Stent repositioning, n

–

4

–

Additional stent insertion, n

–

4

–

Stent location, n (%)

Other**
Stent-related complications

Therapeutic interventions

*, P value comparing characteristics of stents among patients who did and did not undergo follow-up bronchoscopy. Each stent type and
location is compared to all other stent types and locations, respectively; **, other stent locations included the left lower lobe (n=3) and the
left upper lobe (n=1); ***, some stents were affected by more than one complication; ****, more than one intervention was performed on
some stents. GT, granulation tissue.
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Table 3 Univariate analysis for the presence of any stent-related complication among patients who underwent follow-up bronchoscopy
Characteristic

Odds ratio

95% CI

P value

Age (>55 vs. ≤55 years)

1.18

0.49–2.84

0.71

Sex (female vs. male)

1.36

0.58–3.21

0.48

Indication for stent placement (malignant vs. benign)

0.93

0.40–2.19

0.88

Trachea

1.00

Reference

–

Carina (Y-stent)

0.72

0.24–2.16

0.56

Left mainstem bronchus

0.95

0.23–3.85

0.94

Right mainstem bronchus

3.25

0.35–30.0

0.30

Bronchus intermedius

2.71

0.76–9.63

0.12

Hybrid

1.00

Reference

–

Metallic

0.09

0.01–0.59

0.01

Straight silicone stent

0.40

0.12–1.40

0.15

Y stent

0.24

0.07–0.80

0.02

T-tube

0.18

0.04–0.80

0.03

Any symptom (yes vs. no)

1.88

0.79–4.45

0.15

Dyspnea (yes vs. no)

2.80

1.06–7.35

0.04

Cough (yes vs. no)

1.77

0.46–6.86

0.41

Respiratory failure (yes vs. no)

0.40

0.12–1.35

0.14

Stent location

Stent type

Symptoms*

*, excess secretions and dysphagia were not analyzed individually as symptoms because their incidence was too small.

Table 4 Univariate analysis for the presence of individual stent-related complications in hybrid compared to non-hybrid stents
Hybrid stents vs. non-hybrid stents

Odds ratio

95% CI

P value

Obstruction by tumor/granulation tissue

0.84

0.34–2.09

0.71

Obstruction by secretions

2.53

1.10–5.84

0.03

Stent migration

6.60

2.16–20.2

0.001

For both malignant and benign airway diseases, airway
stents provide significant symptomatic benefit, decrease

highlights the potential role of follow-up bronchoscopy as a
stent surveillance method.

airflow obstruction, and improve quality of life (1-11).

The reported stent-related complication rate has varied

Despite many benefits, airway stents are foreign bodies

in the literature (mostly 40–60%, and as high as 87% at

prone to complications (21). Even with frequent stent-

20 months), based on the study population and the types/

associated complications, guidelines for surveillance and

material of airway stents deployed (2,13-17,22). The

maintenance of these stent remain inadequate18. This study

complication rate in our study (69%) falls within this range.

confirms that stent-related complications are common, and

Stent complications have often been shown to occur
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within the first 2 to 3 months following stent placement
and some, such as stent migration and granulation tissue
formation, may manifest as early as 3 days later (4,12,23,24).
In fact, nineteen stents (19.0%) in our study were found to
have complications within 5 days of insertion.
In addition, loss of airway stent patency is most rapid
during the first year following stent placement, often
requiring bronchoscopic interventions (6,12,15). For
metallic stents, neoepithelialization with incorporation
of the stent within the airway wall can occur as early as
3–6 weeks; complications during removal of these stents
were more likely to occur the longer they had been in
place (25,26).
In benign airway stenosis, temporary airway stents can
potentially provide long-term airway patency even after the
stent removal. Appropriate surveillance and maintenance
of these stents is essential, as longer these stents are kept,
the higher the likelihood of long-term airway patency
after stent removal (27). These findings from our and
other studies suggest that stent-related complications are
common, and can occur early, and often require early
therapeutic intervention to maintain airway patency.
While presence of symptoms in patients after
stent placement is a clear indication for a followup bronchoscopy, the method of stent surveillance in
asymptomatic patients is less clear and unestablished.
In one study, routine surveillance bronchoscopy of
asymptomatic patients within 2 to 3 months after stent
insertion did not result in detection of high incidence of
stent-related complications (28). In our study, however,
absence of symptoms did not always correlate with stentassociated complications. The two studies are similar in size
and patient population, but our study examined multiple
stent types (metallic, silicone, and hybrid), rather than
silicone stents alone, which may explain the difference
in findings. Our study suggests that routine surveillance
bronchoscopy, regardless of symptomatic status, may play a
role in early detection of stent-related complications, with
a goal to delay likely future sequelae of post-obstructive
pneumonia and respiratory failure. The impact of routine
surveillance bronchoscopy on patient mortality, morbidity,
hospitalization, and overall health costs remains to be
determined.
A survey by Hoag et al. revealed that 61% of
interventional pulmonologists discovered stent-related
complications via various surveillance methods, including
physical examination, chest radiography, computed
tomography (CT), bronchoscopy and fluoroscopy (18).
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There is limited data to compare the efficacy of these
different surveillance methods at detecting stent-related
complications. Small studies showed that CT was an
accurate, non-invasive method to evaluate airway stents
and airway patency, though unable to characterize stent
epithelialization and subtle stenoses (29,30).
To our knowledge, our study includes the largest
number of hybrid stents ever studied. The hybrid stent
is a self-expanding stent, which combines the features of
metallic and silicone stents, with a hydrophilic coating
and completely covered nitinol framework. Our study
shows that hybrid stents are associated with higher rates
of migration and significant obstruction by secretions,
compared to other stents. Smaller studies have also reported
the occurrence of these complications. In one study, which
evaluated recurrent bronchus intermedius strictures in
lung transplant recipients, mucus buildup was detected in
all 6 stents, and immediate migration was seen in 5 out of
6 stents (31). In another study, four out of five hybrid stents
were affected by migration in benign airway stenoses (13).
The strengths of our study include the relatively large
patient sample, the diversity of indications for stent
placement, and the variety of stents used. The main
limitation of our study was its retrospective nature; as such,
multicenter, prospective studies are needed to validate the
optimal period of surveillance bronchoscopy for longterm benefits. Another limitation of our study was that
about a third of our patients did not undergo follow-up
bronchoscopy due to primarily to death or transition to
hospice care. Furthermore, we did not evaluate for stentassociated respiratory tract infection, which is known to
occur in 15 to 20% of patients with stents (16,32,33).
Finally, it remains to be determined, whether the early
bronchoscopic detection of stent-related complications in
asymptomatic patients can prevent subsequent symptom
development or clinical deterioration. Prospective trials
are needed to adequately define the role of surveillance
bronchoscopy.
Conclusions
Surveillance bronchoscopy within 4 to 6 weeks of
stent placement may be useful for early detection of
complications and their subsequent management,
regardless of symptomatic status and indication for stent
placement. Prospective multicenter studies are needed
to compare optimal surveillance methods and determine
how surveillance bronchoscopy affects patient mortality,
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morbidity and healthcare costs.
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